floxuridine

5-フルオロデオキシウリジン。フロクスウリジン 　

WordNet

1. antineoplastic drug used to treat some cancers; can cause loss of hair

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/05/16 04:02:17」(JST)

wiki en

[Wiki en表示]

Floxuridine

Systematic (IUPAC) name
5-Fluoro-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidine-2,4-dione
Clinical data
AHFS/Drugs.com	monograph
MedlinePlus	a682006
Pregnancy category	(US): D
Routes of administration	Intra-arterial
Identifiers
CAS Number	50-91-9 Y
ATC code	none
PubChem	CID 5790
IUPHAR/BPS	4801
DrugBank	DB00322 Y
ChemSpider	5586 Y
UNII	039LU44I5M Y
KEGG	D04197 Y
ChEBI	CHEBI:60761 Y
ChEMBL	CHEMBL917 Y
Chemical data
Formula	C9H11FN2O5
Molar mass	246.192 g/mol
SMILES FC=1C(=O)NC(=O)N(C=1)[C@@H]2O[C@@H]([C@@H](O)C2)CO
InChI InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1 Y Key:ODKNJVUHOIMIIZ-RRKCRQDMSA-N Y
(verify)

Floxuridine (also 5-fluorodeoxyuridine) is an oncology drug that belongs to the class known as antimetabolites. The drug is most often used in the treatment of colorectal cancer.

Pharmacology

Floxuridine, an analog of 5-fluorouracil, is a fluorinated pyrimidine.

Mechanism of action

Floxuridine works because it is broken down by the body into its active form, which is the same as a metabolite of 5-Fluorouracil.

History

Floxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the initial work on 5-fluorouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to F H Faulding, which became Mayne Pharma.

Suppliers

In the US the drug is supplied by APP Pharmaceuticals, LLC; Hospira, Inc.; and Bedford Laboratories.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 大腸癌の肝転移に対する非外科的局所治療戦略 nonsurgical local treatment strategies for colorectal cancer liver metastases
• 2. 限局進行性胆管癌に対する治療選択肢 treatment options for locally advanced cholangiocarcinoma
• 3. 抵抗性または再発性の妊娠性絨毛腫瘍のマネージメント management of resistant or recurrent gestational trophoblastic neoplasia
• 4. 肝疾患を有する患者における化学療法による肝毒性および用量調整 chemotherapy hepatotoxicity and dose modification in patients with liver disease
• 5. 切除可能大腸癌の肝転移のマネージメント management of potentially resectable colorectal cancer liver metastases

English Journal

• Synthesis and biological activity of salinomycin conjugates with floxuridine.

• Huczyński A1, Antoszczak M2, Kleczewska N2, Lewandowska M2, Maj E3, Stefańska J4, Wietrzyk J3, Janczak J5, Celewicz L2.
• European journal of medicinal chemistry.Eur J Med Chem.2015 Mar 26;93:33-41. doi: 10.1016/j.ejmech.2015.01.045. Epub 2015 Jan 27.
• As part of our program to develop anticancer agents, we have synthesized new compounds, which are conjugates between well-known anticancer drug, floxuridine and salinomycin which is able to selectivity kill cancer stem cells. The conjugates were obtained in two ways i.e. by copper(I) catalysed click
• PMID 25644674

• Palladium-mediated dealkylation of N-propargyl-floxuridine as a bioorthogonal oxygen-independent prodrug strategy.

• Weiss JT1, Carragher NO1, Unciti-Broceta A1.
• Scientific reports.Sci Rep.2015 Mar 19;5:9329. doi: 10.1038/srep09329.
• Herein we report the development and biological screening of a bioorthogonal palladium-labile prodrug of the nucleoside analogue floxuridine, a potent antineoplastic drug used in the clinic to treat advanced cancers. N-propargylation of the N3 position of its uracil ring resulted in a vast reduction
• PMID 25788464

• Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.

• DʼAngelica MI1, Correa-Gallego C, Paty PB, Cercek A, Gewirtz AN, Chou JF, Capanu M, Kingham TP, Fong Y, DeMatteo RP, Allen PJ, Jarnagin WR, Kemeny N.
• Annals of surgery.Ann Surg.2015 Feb;261(2):353-60. doi: 10.1097/SLA.0000000000000614.
• PURPOSE: Evaluate conversion rate of patients with unresectable colorectal-liver metastasis to complete resection with hepatic-arterial infusion plus systemic chemotherapy including bevacizumab (Bev).PATIENTS AND METHODS: Forty-nine patients with unresectable colorectal liver metastases (CRLM) were
• PMID 24646562

Japanese Journal

• Interaction of Intestinal Nucleoside Transporter hCNT2 with Amino Acid Ester Prodrugs of Floxuridine and 2-Bromo-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole(Pharmacology)

• Biological & pharmaceutical bulletin 29(2), 247-252, 2006-02-01
• NAID 110005663953

• Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer

• J Clin Oncol. 21, 3303-3309, 2003
• NAID 30022789173

• Quality of life and survival with continuous hepaticaetery floxuridine infusion for colorectal liver metastases

• Lancet 344, 1255-1260, 1994
• NAID 80007926031

Related Links

• Floxuridine - Drug Information - Chemocare

(floks-YOOR-ih-deen) Trade names: FUDR ® Chemocare.com uses generic drug names in all descriptions of drugs. FUDR is the trade name for floxuridine. In some cases, health care professionals may use the trade name ...

• Floxuridineとは - goo Wikipedia (ウィキペディア)

Floxuridineとは？goo Wikipedia (ウィキペディア) 。出典：Wikipedia（ウィキペディア）フリー百科事典。 Floxuridineとは - goo Wikipedia (ウィキペディア) gooトップ サイトマップ スタートページに設定 RSS ヘルプ メニューへスキップ 本文へ ...

Related Pictures

---

★リンクテーブル★

リンク元	「5-フルオロデオキシウリジン」

「5-フルオロデオキシウリジン」

　　[★]

英

5-fluorodeoxyuridine, FUdR

同

フロクスウリジン floxuridine, 5-フルオロデオキシウリジン 5-fluoro-2′-deoxyuridine 5-FUdR

• 抗悪性腫瘍薬